|
Renalytix PLC - London-based kidney health-focused diagnostics company - Says that two scientific presentations proving the utility of KidneyIntelX in minorities and veterans have been accepted at the upcoming National Kidney Foundation Spring Clinicals Conference taking place in Austin, Texas. In a clinical decision effectiveness study, KidneyIntelX classified more black versus non-black patients as high risk for progression of chronic kidney disease, resulting in increased prescription of SGLT2-inhibitor. Additional results also showed how KidneyIntelX is aligned with the Veteran’s Health Administration care practice guidelines for risk assessment in early-stage kidney disease and the introduction of novel therapies and timely referral to clinical specialists. Current stock price: 97.90 pence, up 13% in London on Wednesday around midday 12 month change: down 56% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
